Julia Peña Asensio-rekin lankidetzan egindako argitalpenak (10)

2024

  1. Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain

    Annals of Pharmacotherapy, Vol. 58, Núm. 2, pp. 140-147

  2. HBsAg level defines different clinical phenotypes of HBeAg(−) chronic HBV infection related to HBV polymerase-specific CD8+ cell response quality

    Frontiers in Immunology, Vol. 15

  3. IL-15 boosts activated HBV core-specific CD8+ progenitor cells via metabolic rebalancing in persistent HBV infection

    iScience, Vol. 27, Núm. 1

2022

  1. Current challenges in the functional cure of HBe-antigen negative chronic hepatitis B

    Revista Espanola de Enfermedades Digestivas, Vol. 114, pp. 441-444

  2. Letter: the probability to predict HBV-specific CD8+ cell response derived from HLA-A2+ may not foresee the functional cure well in Asian off-therapy cohort—authors' reply

    Alimentary Pharmacology and Therapeutics

  3. Model to predict on-treatment restoration of functional HBV-specific CD8+ cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B

    Alimentary Pharmacology and Therapeutics, Vol. 55, Núm. 12, pp. 1545-1559

2021

  1. Anti-pd-1/pd-l1 based combination immunotherapy to boost antigen-specific cd8+ t cell response in hepatocellular carcinoma

    Cancers, Vol. 13, Núm. 8

  2. Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C

    Cells, Vol. 10, Núm. 3

2020

  1. Tumor necrosis family receptor superfamily member 9/tumor necrosis factor receptor-associated factor 1 pathway on hepatitis C viral persistence and natural history

    World Journal of Hepatology, Vol. 12, Núm. 10, pp. 754-765

2018

  1. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?

    World Journal of Gastroenterology, Vol. 24, Núm. 17, pp. 1825-1838